Medicenna Therapeutics Corp has seen a decline in its stock performance this week, with no significant news driving the changes. Here's a closer look at the current state of MDNA.TO.
This week, Medicenna Therapeutics Corp (MDNA.TO) is experiencing a downward trend in its stock performance, marking a 4.11% decline over the past week. Despite the lack of major company news, recent headlines indicate ongoing developments related to public offerings that may influence investor sentiment.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$32.31M
52W high
$1.97
52W low
$0.34
1W change
-4.11%
Beta
1.89
Analyst Price Targets
Based on analyst covering MDNA
Wall Street analysts forecast MDNA stock price to rise 814.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+814.3% Upside
Current Price
C$0.35
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
36.0%
Annualized
90-Day Vol
69.3%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$0.29
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.33 | C$0.29 – C$0.37 |
| 60 trading days | C$0.31 | C$0.26 – C$0.37 |
| 90 trading days | C$0.29 | C$0.24 – C$0.36 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While Medicenna's stock has dipped recently, analysts remain optimistic with a substantial target price indicating potential upside. Investors should consider the current technical indicators and market conditions when evaluating their positions.
Medicenna's stock is currently trading at C$0.35, down 4.11% this week.
The stock has a 52-week range of C$0.34 to C$1.97, indicating significant volatility over the past year.
Bull case
Analysts have set an average target price of C$3.20 for Medicenna, suggesting a potential upside of over 800%. This positive outlook is backed by the company's ongoing clinical trials and strategic initiatives that could drive future growth.
Bear case
The stock's performance has been inconsistent, with a year-to-date decline of 65%. This sharp drop means investors should proceed with caution. The company's negative profit margin and high beta signal volatility, which may be a concern for those looking to minimize risk.
Price Action Overview
Medicenna's stock closed at C$0.35, reflecting no change over the last day but a notable decline of 4.11% over the past week. The stock has struggled significantly this year, down 65% year-to-date.
Recent Company News
While there were no significant announcements from Medicenna this week, recent headlines include the finalization of terms for a public offering, where units are priced at C$0.50 each. This offering may provide the company with necessary capital for ongoing projects.
Technical Picture
Currently, Medicenna's stock is trading below both its 50-day moving average of C$0.43 and its 200-day moving average of C$0.84, indicating a bearish trend. The stock has a beta of 1.89, suggesting higher volatility compared to the broader market. The latest trading volume was 30,502 shares, well below the 20-day average volume of 76,616 shares, which may indicate lower investor interest.
Advertisement
